A team at King's College London pulled keratin out of sheep's wool, turned it into a surgical membrane, and implanted it into rat skulls with holes too large to heal on their own. Measured by sheer volume, the wool material was lost. Collagen, the material surgeons have leaned on for decades, produced more bone.
The wool version produced better-organized bone.
That distinction, reported in the journal Biomaterials Advances and back in circulation this month after a fresh round of coverage, is why a farm byproduct keeps appearing in regenerative medicine papers. Under imaging and histology, the keratin-guided tissue came back more organized, with better-aligned fibers and greater structural stability, more closely resembling healthy natural bone than the tissue formed under collagen.
Collagen Made More Bone. Keratin Makes Better Bone.
Guided bone regeneration is a workhorse procedure. A barrier membrane is laid over a defect so fast-growing soft tissue cannot crowd into the space while slower bone rebuilds underneath. It is standard in dental implant site preparation, periodontal surgery, and craniofacial reconstruction.
Collagen membranes dominate that market and have known weaknesses. The study team lists them plainly: premature resorption, insufficient stability, limited capacity to actively drive bone formation, and potential immunogenicity. Those shortcomings matter most in large, unstable, or load-bearing defects, where a membrane that collapses or degrades early compromises the whole repair.
The King's team, led by Dr. Sherif Elsharkawy and first-author Sara Gamea, built keratin membranes stabilized by the protein's internal interactions and controlled chemical crosslinking. The full report describes membranes that resisted fibroblast invasion, integrated with surrounding tissue, and stayed intact through healing.
What the Rats Actually Received
Before any animal work, the membranes were seeded with primary human bone marrow stromal cells. Those cells stayed highly viable and moved through a sequence of bone-forming differentiation, with significant upregulation of both early and late osteogenic markers. Mineralized keratin, in particular, drove osteogenic gene expression and organized matrix formation.
The in vivo test used a rat critical-size calvarial defect model, meaning skull defects deliberately made large enough not to close without intervention. Over several weeks, the researchers tracked how new bone bridged the gap.
"We are really excited to show for the first time how a wool-based material has been successfully tested in a living animal to repair bones," Elsharkawy said in a statement from King's College London. He framed the result as a category shift rather than a product: "It positions keratin as a potential new class of regenerative biomaterial that could challenge the long-standing reliance on collagen."
Both claims should be read as what they are. This is a rodent study in non-load-bearing skull bone, with no human participants, no clinical trial, and no regulatory submission. Rat calvarial healing has a long history of failing to predict what happens in a human jaw under chewing forces.
Wool Keratin Has Been in Patients Before, with Mixed Results
Keratin from wool has already undergone human testing in a different tissue, and the results are more instructive than they first appear. Keratin4VLU, a randomized controlled trial conducted at the University of Auckland with sites in New Zealand and Australia, compared wool-derived keratin dressings with usual-care dressings for slow-healing venous leg ulcers.
It did not work. Across 143 randomized participants, the trial found no significant difference between groups in healing at 24 weeks, change in ulcer area, time to complete healing, or adverse event rates.
That is a real result, and it cuts both ways. It shows that wool keratin can be manufactured to clinical standards and applied to patients without a safety signal, which is a meaningfully different starting point from a compound that has never left a laboratory. It also shows that promising laboratory behavior in keratin has already failed to translate once.
Bone is a harder problem than skin anyway. A wound dressing sits on the surface and comes off. A regenerative membrane must maintain its shape and mechanical properties within the body for weeks.
The Sustainability Argument, and Its Limits
Wool is abundant and frequently discarded. A 2017 review in the RSC journal Biomaterials Science reported that global wool production exceeds 2.5 million tonnes per year, noting that low-grade wool and slaughterhouse trimmings cannot be used by the textile industry and end up as waste.
That is a genuine supply-chain argument, and it is also the part of this story most likely to be oversold. The same review explicitly states that dissolving and extracting keratin is a more difficult process than with other natural polymers, including collagen, and that scaling it depends on finding a fast, cost-effective method. Cheap raw materials do not translate into a cheap medical device. Extraction, purification, crosslinking, sterilization, batch consistency, and regulatory clearance dominate the cost of any implantable product, and none of those have been demonstrated at scale for these membranes.
The honest position is that a research group has shown a plausible alternative to collagen in one animal model, in one bone site, with one outcome measure favoring it and another favoring the incumbent. Larger animal work in load-bearing defects, then human trials, would need to follow. Patients scheduled for bone grafting or implant surgery should discuss materials with their own clinician. Nothing described here is available as a treatment.
Key Questions Answered
What is a guided bone regeneration membrane?
A barrier placed over a bone defect during surgery to keep soft tissue from filling the space while bone regrows underneath.
Did the wool material outperform collagen?
Partly. Collagen produced greater total bone volume. The keratin membranes produced bone with better-organized architecture and better-aligned fibers.
Was this tested in people?
No. Human bone marrow stromal cells were cultured in the laboratory, but the implant work was performed in rats.
Has wool keratin ever been used in patients?
Yes, for a different problem, and it failed to beat standard care. A randomized trial of wool-derived keratin dressings for venous leg ulcers found no significant healing benefit.
Why use wool at all?
Keratin is abundant in wool, much of which is discarded as agricultural waste. Extracting and purifying it, however, is chemically demanding.
How far is this from a clinical product?
Far. Larger animal studies, load-bearing defect models, manufacturing scale-up, and human trials would all come first.
